Europe Is Won Before Launch: the Leadership, Access and Evidence Playbook for Rare Disease Biotech.
)
)
Rare diseases affect an estimated 36 million people across Europe, yet access to life-changing treatments remains one of healthcare's greatest challenges. While advances in genomics, precision medicine and orphan drug development have accelerated innovation, scientific breakthroughs alone are no longer enough to ensure patient access.
Today, success in Europe's rare disease landscape is increasingly determined by the ability to navigate complex health technology assessments (HTA), reimbursement negotiations, evidence requirements and increasingly fragmented access pathways. For biotech and pharmaceutical companies, the challenge is not simply developing innovative therapies, it's securing sustainable patient access across diverse European markets.
Drawing on market data and insights from senior commercial, medical and market access leaders across Europe, this whitepaper explores the strategies, evidence frameworks and leadership capabilities required to successfully launch rare disease therapies and improve outcomes for patients.
Download the whitepaper to discover why, in Europe, rare disease success is won before launch.
- Whitepaper
- Executive Search
)
Sofia specialises in board, C-suite, and senior leadership appointments in healthcare and life sciences in EMEA and the US. Prior to joining Venari Partners, she was a key member of the Healthcare practice at Russell Reynolds Associates. She was also a Principal at True Search. Additionally, Sofia is a published scientist. She completed her PhD in Life Sciences in collaboration with Imperial College London, where she also held a postdoctoral position under the Bill & Melinda Gates Foundation grant. Her research focused on malaria, gene editing technologies and infectious disease. Alongside her academic work, Sofia co-founded a startup focused on sustainable, plant-based products, giving her early exposure to business building, fundraising, and commercial strategy.
View Full Profile)
)
)
)
)
)
